Skip to main content
Chemical Enhancement of In Vitro and In Vivo Direct Cardiac Reprogramming.
- Author(s): Mohamed, Tamer MA
- Stone, Nicole R
- Berry, Emily C
- Radzinsky, Ethan
- Huang, Yu
- Pratt, Karishma
- Ang, Yen-Sin
- Yu, Pengzhi
- Wang, Haixia
- Tang, Shibing
- Magnitsky, Sergey
- Ding, Sheng
- Ivey, Kathryn N
- Srivastava, Deepak
- et al.
Published Web Locationhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340593/
No data is associated with this publication.
BackgroundReprogramming of cardiac fibroblasts into induced cardiomyocyte-like cells in situ represents a promising strategy for cardiac regeneration. A combination of 3 cardiac transcription factors, Gata4, Mef2c, and Tbx5 (GMT), can convert fibroblasts into induced cardiomyocyte-like cells, albeit with low efficiency in vitro.
MethodsWe screened 5500 compounds in primary cardiac fibroblasts to identify the pathways that can be modulated to enhance cardiomyocyte reprogramming.
ResultsWe found that a combination of the transforming growth factor-β inhibitor SB431542 and the WNT inhibitor XAV939 increased reprogramming efficiency 8-fold when added to GMT-overexpressing cardiac fibroblasts. The small molecules also enhanced the speed and quality of cell conversion; we observed beating cells as early as 1 week after reprogramming compared with 6 to 8 weeks with GMT alone. In vivo, mice exposed to GMT, SB431542, and XAV939 for 2 weeks after myocardial infarction showed significantly improved reprogramming and cardiac function compared with those exposed to only GMT. Human cardiac reprogramming was similarly enhanced on transforming growth factor-β and WNT inhibition and was achieved most efficiently with GMT plus myocardin.
ConclusionsTransforming growth factor-β and WNT inhibitors jointly enhance GMT-induced direct cardiac reprogramming from cardiac fibroblasts in vitro and in vivo and provide a more robust platform for cardiac regeneration.
Item not freely available? Link broken?Report a problem accessing this item